ADHD in adults: what it’s like living with the condition – and why many still struggle to get diagnosed

Jul 2, 2021

4 min



Many of us think of ADHD (attention deficit hyperactivity disorder) as a childhood condition – which is typically when it’s diagnosed. But a growing number of people are sharing their experiences of being diagnosed with ADHD in adulthood. Social media has even played a role in this, with reports of people going to see their doctor after first learning about symptoms on TikTok. In fact, around 2.5% of adults are thought to live with ADHD – including us.


Yet despite this growing awareness, many adults continue to struggle to get a diagnosis.


ADHD is a genetic neurodevelopmental disorder, in which the brain grows differently, lacking action from specific chemicals involved in pleasure and reward. This means ADHD brains often search for ways to stimulate these chemicals, which is why people can experience inattentiveness, hyperactivity and impulsivity.


Common traits of ADHD include:


  • Not following through on longer tasks (or not starting them)
  • Getting distracted by other tasks or thoughts
  • Seeking out risk or activities that provide immediate reward
  • Restlessness (either outwardly or internally)
  • Interrupting other people (without wanting to)
  • Symptoms are similar for both adults and children, although elements of them differ or change as we age. For example, inattention is the most persistent symptom in adults.

ADHD can be debilitating and is associated with higher likelihood of lower quality of life, substance use issues, unemployment, accidental injuries, suicide and premature death. In addition, ADHD can cost adults around £18,000 per year because of things like medical care or paying for social support.


It’s also commonly associated with a wide range of co-existing conditions in adults.


For example, depression is almost three times more prevalent in adults with ADHD. And nearly half of all adults with ADHD also have bipolar spectrum disorder.


Around 70% of adults with ADHD also experience emotional dysregulation, which can make it more difficult to control emotional responses. It’s also thought that almost all adults with ADHD have rejection sensitive dysphoria, a condition where perceived rejection or criticism can cause extreme emotional sensitivity or pain.


On top of this, adults with ADHD may have poor working memory – such as being unable to remember a simple shopping list – and “time blindness” (the inability to perceive time). Some may also have oppositional defiant disorder, which means they often react poorly to perceived orders or rules.


While none of these co-existing conditions are used to diagnose ADHD, they can make ADHD feel all the more difficult to live with.



Being diagnosed


Getting an ADHD diagnosis as an adult in the UK is notoriously difficult – with reports of some people waiting up to five years.


Waiting for a diagnosis is common for adults with ADHD. Roman Kosolapov/ Shutterstock


This is because you can only be diagnosed by a specialist psychiatrist. But even with a referral to a specialist, a person has to show clear evidence of almost all ADHD traits, having had these traits since childhood, and that they’re having a serious affect on their life – such as causing issues with work, education, or maintaining relationships.


For us, our experiences of being diagnosed with ADHD aren’t all that different from what other adults have gone through.


Like many people I (Alex) was only diagnosed with ADHD “by accident” after being referred to an NHS psychiatrist to get help with (what I now know to be) alcohol self-medication. Because of my ADHD, my brain demands quite extreme inputs most of the time.


Ironically, I’ve published scientific papers on ADHD and – probably due to a classic ADHD lack of self-awareness – it didn’t cross my mind that I could have it. The “label” has since helped me move away from feeling broken toward an understanding of my behaviour.


My main challenges remain prioritising tasks based on importance (instead of excitement) and quite extreme anti-authority behaviour (sometimes called oppositional defiance). I am also a terrible spectator, struggling to attend conference talks or sit still at the theatre – it can feel like physical pain.


On the other hand, I (James) was diagnosed pretty quickly because I used a private clinic – though there was still a long wait for medication. Yet I’d known for five years before this that I probably had ADHD, but coped with it well until the pandemic. The added pressure of isolation and increased workload impacted my mental health, so I sought a diagnosis.


Now diagnosed and medicated, life is getting easier to cope with – although there are still many challenges every day. I frequently get anxiety about the silliest things, like talking to a friend, but appearing on television is fine.


On a daily basis I forget many simple things, such as where I left my keys, or that I am running a bath. I struggle immensely with controlling my emotions and with rejection especially. For example, when no one responded to a joke I made about my ADHD on a senior management messaging group I was tempted to quit my job. I am utterly unable to pay full attention in meetings or seminars and cannot control my impulse purchasing.


While there’s a growing recognition of ADHD in adults, many people still live with it undiagnosed for any number of reasons – sometimes even because they’re unaware that what they experience is actually different from other people.


Understanding the condition in adults, taking it more seriously as a disorder, raising awareness of it, and investing in services to improve diagnosis times are key. Diagnosis opens the door to treatment, which can have a marked impact on living with the disorder – such as improving self-esteem, productivity and quality of life.


This article was co-written by Dr James Brown (Aston University) and Dr Alex Connor (University of Birmingham)



Powered by

You might also like...

Check out some other posts from Aston University

2 min

Aston University economists say Prime Minister can reduce UK trade vulnerability with China visit

Greenland episode exposed UK’s lack of effective response to economic coercion from allies Research shows tariff retaliation would have cost the average UK household up to £324 per year Economists say China visit is “portfolio risk management” – diversification reduces vulnerability. The Prime Minister’s visit to China – the first by a British PM since 2018 – is an opportunity to reduce the UK’s vulnerability to economic coercion, according to new research from Aston University. A policy paper from Aston Business School’s Centre for Business Prosperity analyses the January 2026 Greenland tariff episode, when President Trump threatened and then withdrew tariffs on eight European countries. The researchers found that the UK had no good options: retaliation would have made Britain worse off, while absorbing the tariffs left Europe without credible deterrence. Director of the centre for business prosperity, Professor Jun Du, said: “The Greenland episode was a wake-up call. When your principal security ally threatens economic coercion, the old assumptions about who is safe and who is dangerous no longer hold. “The PM’s China visit should be framed as portfolio risk management – building diversified trading relationships that reduce the UK’s exposure to any single partner. Just as investors don’t put all their money in one stock, countries shouldn’t put all their trade into one basket. A UK with multiple strong partnerships is harder to pressure, whether the pressure comes from Washington or Beijing.” The research found that coordinated UK–EU tariff retaliation would have cost British households up to £324 per year – the worst outcome modelled. But the authors argue that Europe has untapped leverage elsewhere: the US runs a €148 billion annual services surplus with the EU, and mutual investment exceeds €5.3 trillion. Associate professor of economics and co-author, Dr Oleksandr Shepotylo, said: “Tariff retaliation fails because it hurts consumers and distorts the economy – the retaliator suffers similarly to the target. But Europe has cards it isn’t playing. Services, investment screening, and regulatory access are pressure points where Europe can respond effectively.” UK exports to China fell by 10.4% in the year to Q2 2025, with goods exports down 23.1% – the sharpest decline among major trading partners. The researchers argue that this closes off the UK’s largest alternative market at precisely the moment US reliability is in question. The paper identifies three priorities for UK policy: Recognise the permanent incentives behind US tariffs. US tariff revenue hit $264 billion in 2025. Trade negotiations alone cannot resolve revenue-driven policy. Build UK–EU coordination on non-tariff instruments. Services, investment, procurement, and regulation offer leverage that tariffs do not. Treat China engagement as portfolio risk management. Concentration in any single market creates vulnerability. Diversification is not about picking sides – it’s about resilience. Professor Du added: “The question for the Prime Minister is whether to use this breathing space to build resilience – or wait for the next Greenland.” To read the policy paper in full, click on this link:

2 min

Medication adherence: Why it matters and how we can improve it – public lecture by Professor Ian Maidment

Professor Ian Maidment is a professor in clinical pharmacy at Aston Pharmacy School His inaugural lecture will explain why patients struggle with taking medication and present possible solutions to the problem Professor Maidment is a former practising pharmacist and an expert in medication optimisation and management in mental health and dementia. Professor Ian Maidment, professor in clinical pharmacy at Aston Pharmacy School, will give a public lecture about his life’s work on 5 February 2025. In his inaugural lecture, Professor Maidment will reflect on his journey from a childhood in Kent to becoming a leading researcher in clinical pharmacy. After more than two decades working in the NHS, in community pharmacy, mental health, dementia care, and leadership roles, he joined Aston University in 2012. His research focuses on the real-world challenges of medication optimisation for patients, carers, and healthcare professionals. The title of Professor Maidment’s lecture is ‘Medication adherence: Why it matters and how we can improve it’. Every year, the UK spends nearly £21 billion on medicines. Yet up to half of people with long-term conditions do not take their medication as prescribed—a problem known as non-adherence. This has profound clinical consequences and significant financial implications for the NHS. Professor Maidment will draw on his experience to explore how factors such as medication burden and side-effects influence adherence, the challenges posed by conditions such as dementia and severe mental illness, the role of pharmacy in supporting adherence and why tackling non-adherence requires a system-wide approach. He will also offer practical solutions to one of healthcare’s most persistent problems. Professor Maidment said: “We need to understand why patients struggle to take their medication and then develop and test solutions that work well.” The lecture on Thursday 5 February 2026 will take place at Aston Business School. In-person tickets are available from Eventbrite. The public lecture will begin at 18:00 GMT with refreshments served from 17:30 GMT. It is free of charge and will be followed by a drinks reception. The lecture will also be streamed online.

3 min

New research partnership to develop biodegradable gloves from food waste for healthcare sector

Knowledge Transfer Partnership between Aston University and PFE Medical to develop a biodegradable clinical glove from food waste The gloves will provide a low-cost, convenient and sustainable alternative to the 1.4bn disposable gloves used in the NHS each year The innovation will reduce clinical waste and costs and help the NHS reach its net zero goals. Aston University and Midlands-based company PFE Medical are teaming up to create biodegradable gloves made from food waste for use in the NHS. They will offer a low-cost, convenient alternative to disposable gloves without compromising patient safety. More than 1.4bn disposable gloves are used by the NHS each year. They create large volumes of clinical waste which has both an environmental and economic cost. The Knowledge Transfer Partnership (KTP) project will develop a more sustainable alternative made from polymers derived from food waste such as orange peel, able to degrade naturally. The gloves will initially be for use during low-risk tasks such as ultrasound scans, rather than in more critical situations such as operating theatres. The gloves would be designed to not only reduce clinical waste and costs in the NHS, but also carbon emissions, helping the NHS reach its goal to be the world’s first net-zero health service. With most personal protective equipment (PPE) currently sourced from Chinese manufacturers, the goal is to develop a biodegradable glove that can be manufactured using a UK supply chain. The challenging project draws on Aston University’s expertise in sustainable polymer chemistry, centred at Aston Institute for Membrane Excellence (AIME). Aston University has one of the largest research groups of polymer chemists in the UK. The project will be led at the University by Professor Paul Topham, director of AIME, and Dr James Wilson, AIME associate member. The research team have chosen to focus on polymers from food waste in order to ensure that the final product can be manufactured sustainably. Most polymers are currently made from petroleum. Polymers made from food waste, ranging from fruit waste to corn or dairy products, have the potential for antioxidant and antibacterial properties if designed appropriately. The team will manipulate the polymer molecules so that they include the right monomers (the smaller units which make up the molecules) in the right location to achieve the properties they require. Critical to the success of the project will be PFE Medical’s commercial and clinical experience of taking new innovations into medical use. It will be the third KTP between Aston University and PFE, following on from successful projects to develop an automated endoscope cleaner, now in use across University Hospitals Birmingham NHS Foundation Trust (UHB). Professor Topham said: “At Aston University, we have a long history of working with industry, of translating fundamental research into solutions for real world problems. This project with PFE Medical provides us with that route, to take our science and engineering and make a difference to peoples’ lives. That’s exactly where, as researchers, we want to be.” Rob Hartley, CEO of PFE Medical, said: “Our previous KTP with Aston University was a phenomenal success, thanks to the brilliant team we had on board. I’m just as excited by this project, which is looking to solve an equally long-standing problem. If we can achieve our goal, then the implications are huge, going far beyond the NHS to all the other situations where people are wearing disposable gloves.” KTPs, funded by Innovate UK, are collaborations between a business, a university and a highly qualified research associate. The UK-wide programme helps businesses to improve their competitiveness and productivity through the better use of knowledge, technology and skills. Aston University is a sector-leading KTP provider, ranked first for project quality, and joint first for the volume of active projects. For further details about this KTP, visit the webpage: www.aston.ac.uk/business/collaborate-with-us/knowledge-transfer-partnership/at-work/pfe-medical.

View all posts